PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference
07 Abril 2022 - 3:00PM
Business Wire
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel therapies for cardiovascular diseases,
today announced that Chief Financial Officer John Sharp will
participate in a fireside chat at the 21st Annual Needham
Healthcare Conference taking place virtually on Thursday, April 14,
2022 from 1:30 – 2:10 pm ET.
Interested parties can access the live and archived webcasts of
the virtual session on the “Events and Presentations” page of the
“Investors” section of the company’s website at www.phasebio.com.
The webcast replay will be available for 90 days after the
conclusion of the live presentation.
About PhaseBio
PhaseBio Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel therapies for cardiovascular diseases.
The Company’s pipeline includes: bentracimab (PB2452), a novel
reversal agent for the antiplatelet therapy ticagrelor; and PB6440,
an oral agent for the treatment of resistant hypertension.
PhaseBio’s proprietary elastin-like polypeptide technology platform
enables the development of therapies with potential for
less-frequent dosing and improved pharmacokinetics, and drives both
internal and partnership drug-development opportunities.
PhaseBio is located in Malvern, PA, and San Diego, CA. For more
information, please visit www.phasebio.com, and follow us on
Twitter @PhaseBio and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220407005866/en/
PhaseBio Investor Contact:
John Sharp Chief Financial Officer (610) 981-6506
john.sharp@phasebio.com
PhaseBio Media Contact: Will
Zasadny Canale Communications, Inc. (619) 961-8848
will.zasadny@canalecomm.com
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Gráfica de Acción Histórica
De May 2023 a May 2024
Real-Time news about PhaseBio Pharmaceuticals Inc (NASDAQ): 0 recent articles
Más de Phasebio Pharmaceuticals (MM) Artículos de Noticias